NEWS HIGHLIGHTS
Published Studies Related to Terbutaline
A randomized, controlled trial of nebulized terbutaline for the first acute bronchiolitis in infants less than 12-months-old. [2009.03]
BACKGROUND: Despite the common clinical practice, the available evidence on the efficacy of bronchodilators therapy for bronchiolitis is conflicting. The aim of this study is to evaluate the efficacy of nebulized terbutaline in bronchiolitis as measured by improvement in clinical score, oxygen saturation or reduction in duration of hospitalization... CONCLUSION: Nebulized terbutaline therapy does not appear effective in treating moderately ill infants with the first acute bronchiolitis.
Terbutaline in myasthenia gravis: A pilot study. [2009.02.15]
The objective of this study was to assess the short-term efficacy and safety of terbutaline, a beta2-adrenergic agonist, in patients with myasthenia gravis (MG) in a randomized, double-blind, placebo-controlled, crossover study. The primary endpoint for efficacy was a reduction of at least 3 points in the quantitative MG score (QMGS)...
Oral nifepidine versus subcutaneous terbutaline tocolysis for external cephalic version: a double-blind randomised trial. [2009.01]
OBJECTIVE: To evaluate oral nifedipine versus subcutaneous terbutaline tocolysis for external cephalic version (ECV). DESIGN: A double-blind randomised trial. SETTING: A university hospital in Malaysia. POPULATION: Non-labouring women with a term singleton fetus in breech presentation or transverse lie suitable for elective ECV... CONCLUSIONS: Bolus subcutaneous terbutaline tocolysis for ECV compared with oral nifedipine resulted in less caesarean deliveries. ECV success rate was not significantly higher. Larger studies are indicated.
Terbutaline and the prevention of nocturnal hypoglycemia in type 1 diabetes. [2008.12]
CONCLUSIONS: Terbutaline may be shown to be effective and safe in the prevention of nocturnal hypoglycemia in type 1 diabetes in a suitably powered randomized controlled trial.
Nifedipine versus terbutaline for tocolysis in external cephalic version. [2008.09]
OBJECTIVE: To study the efficacy of nifedipine compared with terbutaline as a tocolytic agent in external cephalic version (ECV)... CONCLUSION: Nifedipine can be used as an alternative for tocolysis in ECV when there are maternal contraindications to beta-sympathomimetics.
Clinical Trials Related to Terbutaline
Terbutaline Concentrations in Blood and Urine [Not yet recruiting]
The purpose of this study is to assess the blood and urine concentrations of terbutaline and
to evaluate the difference between inhaled and oral terbutaline in order to distinguish
treatment with terbutaline from doping with terbutaline in a doping control.
Comparing Symbicort As-Needed or Bricanyl As-Needed or Pulmicort Once Daily + Bricanyl As-Needed in Asthma Patients [Not yet recruiting]
1. The primary objective of this study is:
- To evaluate the magnitude of the protective effect of the combination of
budesonide and formoterol on an as-needed basis compared to the use of terbutaline
as-needed on exercise induced bronchoconstriction in adults and adolescents with
mild intermittent asthma
2. The secondary objectives of this study are:
- To evaluate the magnitude of the protective effect of the combination of
budesonide and formoterol as-needed compared to regular once daily use of
budesonide plus terbutaline as-needed on exercise induced bronchoconstriction in
adults and adolescents with mild intermittent asthma
- To evaluate safety of budesonide/formoterol as-needed, terbutaline as-needed and
regular use of budesonide + terbutaline as-needed as terms of adverse event
Prn Budesonide/Formoterol Versus Regular Budesonide/Formoterol Plus Prn Terbutaline in Mild-Moderate Asthma [Recruiting]
Study No. 001 about Budesonide/Formoterol use in ASthMA sponsored by Agenzia Italiana del
FArmaco (Italian Drug Agency) (AIFA-ASMA-BF-001) The aim of the study is to verify whether
asthma not controlled by low doses inhaled corticosteroids, thus in need for step up
therapy, can be equally controlled by guidelines recommended regular bid treatment with long
acting beta agonist/inhaled corticosteroid (ICS/LABA) combination or the symptom driven use
of an ICS/LABA combination in the absence of maintenance therapy. The study is designed to
be able to evaluate the non inferiority of regular placebo plus prn inhaled
budesonide/formoterol (experimental treatment) versus regular, twice daily 160/4. 5 mcg
inhaled budesonide/formoterol combination plus prn inhaled terbutaline (guidelines
recommended treatment).
Study to Investigate the Efficacy of Symbicort SMART. [Recruiting]
The primary objective of this study is to compare the efficacy of Symbicort SMART
(Symbicort Turbuhaler 160/4. 5μg, one inhalation bid plus as needed) with Symbicort
Turbuhaler 160/4. 5μg, one inhalation bid plus terbutaline Turbuhaler 0. 4 mg as needed, as
asthma therapy
Effects of Advair® in Outpatients With Chronic Obstructive Pulmonary Disease (COPD) Acute Exacerbation [Not yet recruiting]
Short course of steroids in COPD exacerbation improves FEV1 and decreases the relapse rate.
However, some concerns remain about using systemic steroids for all patients with acute
exacerbation. Their short-term advantages may be outweighed by the occurrence of adverse
side effects such as hyperglycemia, which is difficult to manage on an outpatient basis. In
this context, the possibility of treating patients with COPD exacerbation with inhaled
steroids having less systemic adverse effects is interesting. The objectives are to compare
relapse rate, lung function, the severity of dyspnea and, systemic and sputum inflammatory
markers in outpatients with acute COPD exacerbations treated with fluticasone/salmeterol
(Advair®) or oral prednisone for 10 days. The hypothesis is that Advair® is as effective as
prednisone in treatment of outpatients with COPD exacerbation. The primary endpoint is to
determine if the relapse rate at one month is equivalent for both treatments. The secondary
endpoints are to compare lung function and dyspnea score and, systemic and sputum
inflammatory markers modulation after 10 days of both treatments. We will recruit 30
outpatients in each group from our COPD clinic. Patients will receive prednisone (40mg/day)
with placebo diskus or Advair® 50/500ug 2 inhalations bid (twice the regular dose) with
placebo pills for 10 days. All patients will receive antibiotics and short-acting
bronchodilators as needed. We expect to demonstrate that the improvement of lung function,
dyspnea, inflammatory markers and relapse rate are equivalent in both treatments suggesting
that Advair® could be a good alternative to prednisone for patients with steroid-induced
hyperglycemia.
|
